- Top Races to Watch in 2016: The Mountain Region
- Top Races to Watch in 2016: New England
- Top Races in 2016: The Midwest
- Top Races to Watch in 2016: The Plains Region
- Republicans Aiming to Register Voters at NASCAR
Some members of Congress apparently do not want agencies to regulate powerful agricultural and pharmaceutical interests in order to protect the public from dangerous risks. Yet, rather than say that — and be held accountable to the electorate for the consequences — they have developed what has become a standard, indeed almost boilerplate pretext to hide their endgame.
Specifically, they have drafted a provision snuck in as a rider to a farm bill that requires agencies to develop elaborate “high standards” for the use of science before they can regulate. Even more problematic than their obscurity is the fact that rather than deferring to the scientific community’s idea of what these high scientific standards should be, congressmen establish the rules of the game on their own. Given their politically-charged origins, it is thus not surprising that these congressionally developed rules are decidedly not in the public interest, nor are they consistent with the true “high standards” of science.
“Good science” sounds like a good thing, like motherhood and apple pie. But, those who spend their lives studying the tedious details of regulations and laws understand that there is plenty at stake in this type of provision. Most obvious is the fact that complying with the additional scientific procedures will slow the agencies’ work further still as they invest added effort into the new ambitious procedures and prepare for inevitable litigation challenges. Lawyers call these types of added mandatory provisions “attachment points,” because high stakes players can latch onto them and use them to bring a seemingly endless stream of legal challenges against the agency, slowing down its work to a snail’s pace.
Never mind that there is no significant evidence of a problem with the agencies’ use of science. Nor is there evidence that when it comes to science, agencies fare worse in understanding how to use it as compared to Congress. In fact, regulators are hired specifically for their scientific and regulatory expertise.
Even more nefarious is the fact that the way “good science” is defined in this provision can actually set the integrity of the agency’s work backwards rather than forwards. The provision, for example, demands that agencies use only research that has been subjected to “well-established scientific processes.” Yet such processes are likely to involve years of peer review and related oversight before a scientific finding can actually be used to support a regulatory policy.
The provision also requires the agency to weigh quantifiable information more heavily than observational or qualitative information. But a critical reader is left scratching her head at the basis for this unilateral legislative decree that quantitative data is more reliable and useful than observational and qualitative research. Even more concerning are the implications once this inflexible weighting rule is implemented in practice.